文献速递临床试验与 GCP基础与转化研究

富血小板血浆注射与安慰剂对踝关节骨关节炎症状和功能的影响:一项随机临床试验

Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该多中心、双盲、安慰剂对照试验纳入100例踝关节骨关节炎患者,随机接受2次超声引导下关节腔内注射富血小板血浆(PRP)或生理盐水。结果不支持PRP注射用于踝关节骨关节炎。

要点

  • PRP注射未显著改善踝关节骨关节炎26周内的症状和功能。
  • 两组AOFAS评分均较基线改善约10-11分,但组间差异无统计学意义。
  • 研究结果不支持PRP注射用于踝关节骨关节炎的临床实践。

核心结论

  • 在踝关节骨关节炎患者中,与安慰剂注射相比,关节腔内PRP注射未在26周内显著改善踝关节症状和功能。
  • 研究结果不支持PRP注射用于踝关节骨关节炎。

研究设计与样本

  • 多中心、区组随机、双盲、安慰剂对照临床试验,在荷兰6个中心进行。
  • 纳入100例视觉模拟量表疼痛评分大于40(范围0-100)且存在胫距关节间隙狭窄的患者。
  • 患者按1:1随机接受2次超声引导下关节腔内注射PRP(n=48)或安慰剂(生理盐水,n=52)。
  • 主要结局为经过验证的美国骨科足踝协会(AOFAS)评分(范围0-100,评分越高疼痛越轻、功能越好;最小临床重要差异为12分),随访26周。

主要发现

  • 共100例随机患者(平均年龄56岁;45例[45%]女性),主要结局无失访。
  • 与基线相比,PRP组AOFAS评分平均改善10分(从63分至73分[95%CI 6-14];P<.001)。
  • 与基线相比,安慰剂组AOFAS评分平均改善11分(从64分至75分[95%CI 7-15];P<.001)。
  • 26周内调整后组间差异为-1(95%CI -6至3;P=.56)。
  • 安慰剂组报告1例严重不良事件,与干预无关;PRP组报告13例其他不良事件,安慰剂组报告8例。

关键数值与推荐

  • 主要结局为AOFAS评分(范围0-100,评分越高疼痛越轻、功能越好;最小临床重要差异为12分)在26周内的变化。
  • 26周内调整后组间差异为-1(95%CI -6至3;P=.56),无统计学意义。

临床怎么用

  • 对于踝关节骨关节炎患者,临床不应常规使用关节腔内PRP注射来改善症状和功能。
  • 应与患者沟通PRP注射缺乏优于安慰剂的证据,避免不必要的干预。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Approximately 3.4% of adults have ankle (tibiotalar) osteoarthritis and, among younger patients, ankle osteoarthritis is more common than knee and hip osteoarthritis. Few effective nonsurgical interventions exist, but platelet-rich plasma (PRP) injections are widely used, with some evidence of efficacy in knee osteoarthritis. OBJECTIVE: To determine the effect of PRP injections on symptoms and function in patients with ankle osteoarthritis. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, block-randomized, double-blinded, placebo-controlled clinical trial performed at 6 sites in the Netherlands that included 100 patients with pain greater than 40 on a visual analog scale (range, 0-100) and tibiotalar joint space narrowing. Enrollment began on August 24, 2018, and follow-up was completed on December 3, 2020. INTERVENTIONS: Patients were randomly assigned (1:1) to receive 2 ultrasonography-guided intra-articular injections of either PRP (n = 48) or placebo (saline; n = 52). MAIN OUTCOMES AND MEASURES: The primary outcome was the validated American Orthopaedic Foot and Ankle Society score (range, 0-100; higher scores indicate less pain and better function; minimal clinically important difference, 12 points) over 26 weeks. RESULTS: Among 100 randomized patients (mean age, 56 years; 45 [45%] women), no patients were lost to follow-up for the primary outcome. Compared with baseline values, the mean American Orthopaedic Foot and Ankle Society score improved by 10 points in the PRP group (from 63 to 73 points [95% CI, 6-14]; P < .001) and 11 points in the placebo group (from 64 to 75 points [95% CI, 7-15]; P < .001). The adjusted between-group difference over 26 weeks was -1 ([95% CI, -6 to 3]; P = .56). One serious adverse event was reported in the placebo group, which was unrelated to the intervention; there were 13 other adverse events in the PRP group and 8 in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with ankle osteoarthritis, intra-articular PRP injections, compared with placebo injections, did not significantly improve ankle symptoms and function over 26 weeks. The results of this study do not support the use of PRP injections for ankle osteoarthritis. TRIAL REGISTRATION: Netherlands Trial Register: NTR7261.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Paget LDA, Reurink G, de Vos RJ, et al. Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial. JAMA. 2021. PMID: 34698782. doi:10.1001/jama.2021.16602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。